These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31950015)

  • 1. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
    Watanabe K; Sugiyama T; Otsuka A; Miyake H
    Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
    Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
    In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.
    Danno T; Iwata S; Niimi F; Honda S; Okada H; Azuma T
    Case Rep Urol; 2021; 2021():9936330. PubMed ID: 34306793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
    Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
    In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
    Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
    In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
    Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
    Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment.
    Meerveld-Eggink A; Graafland N; Wilgenhof S; Van Thienen JV; Lalezari F; Grant M; Szabados B; Abu-Ghanem Y; Kuusk T; Boleti E; Blank CU; Haanen JBAG; Powles T; Bex A
    Eur Urol Open Sci; 2022 Jan; 35():54-58. PubMed ID: 35024632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
    Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
    Front Oncol; 2019; 9():1033. PubMed ID: 31649889
    [No Abstract]   [Full Text] [Related]  

  • 11. Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review.
    Zhou W; Huang J; He Q; Luo Q; Zhang X; Tao X; Dong H; Tu X
    Front Oncol; 2021; 11():764352. PubMed ID: 34820330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
    Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
    Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
    Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
    Front Immunol; 2022; 13():980456. PubMed ID: 36238308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
    Okuno Y; Tanaka R; Mikami K; Takeuchi T
    Hinyokika Kiyo; 2020 Jan; 66(1):13-17. PubMed ID: 32028750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Sazuka T; Fujimoto A; Sato H; Arai T; Imamura Y; Sakamoto S; Ikeda JI; Ichikawa T
    IJU Case Rep; 2021 Nov; 4(6):355-358. PubMed ID: 34755054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.
    Okada T; Hamamoto S; Etani T; Naiki T; Sue Y; Banno R; Yamada K; Sakakura T; Yasui T
    Int Cancer Conf J; 2020 Apr; 9(2):88-91. PubMed ID: 32257760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
    Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab.
    Fuchizawa H; Kijima T; Takada-Owada A; Nagashima Y; Okazaki A; Yokoyama M; Nishihara D; Ishida K; Kamai T
    IJU Case Rep; 2021 Sep; 4(5):333-337. PubMed ID: 34497997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
    Oya M; Tajima Y; Kabu K
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1397-1404. PubMed ID: 31530779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.